Global R&D Pipeline
My Favorite
Hot Targets:
PSMA
Back
Total number of drugs
430
Phase II and later clinical stages
7.9%
Involving companies
455
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18F-PSMA-1007 | 18F-PSMA-1007 | Peptide Conjugate Radionuclide Diagnostic radiopharmaceuticals | Neoplasms Urogenital Diseases | PSMA modulators | German Cancer Research Center | ABX advanced biochemical compounds GmbH Centre For Probe Development & Commercialization NewcureM | Approved | - | South Korea | 2024-12-11 | - | - | PSMA analogue | - | 18 F | - | 18F-PSMA-1007 | - | - | detail > | |
| Technetium Tc 99m trofolastat | Technetium Tc 99m trofolastat | Diagnostic radiopharmaceuticals Radionuclide Drug Conjugates (RDC) | Neoplasms Urogenital Diseases | PSMA inhibitors | Progenics Pharmaceuticals, Inc. | ROTOP Radiopharmacy GmbH PDRadiopharma, Inc. Lantheus Medical Imaging, Inc. | Approved | - | United Kingdom | 2025-03-27 | - | - | - | - | 99m Tc | - | Technetium Tc 99m trofolastat | - | - | detail > | |
| Vincristine Sulfate | Vincristine Sulfate | Small molecule drug | Neoplasms Immune System Diseases Nervous System Diseases Congenital Disorders Hemic and Lymphatic Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | PSMA inhibitors | Eli Lilly & Co. | Libbs Farmacêutica Ltda. Pfizer Inc. Jiangsu Qinfen Pharmaceutical Co., Ltd. Yangzhou Pharmaceutical Co., Ltd. Seagen, Inc. Eli Lilly Japan KK Amgen, Inc. Nippon Kayaku Co., Ltd. Teva Pharmaceuticals USA, Inc. | Approved | Approved | China Japan Brazil | 1963-07-10 | 1982-01-01 | Accelerated Approval（United States） Orphan Drug（United States） | - | - | - | - | Vincristine Sulfate | - | - | detail > | |
| Capromab Pendetide | Capromab Pendetide | Radiolabeled antibody Diagnostic radiopharmaceuticals | Neoplasms Urogenital Diseases | PSMA inhibitors | EUSA Pharma, Inc. | CytoGen, Inc. | Approved | - | United States | 1996-10-28 | - | - | capromab | - | 111 In | - | Capromab Pendetide | IgG1 - kappa | - | detail > | |
| Gallium GA-68 Gozetotide | Gallium GA-68 Gozetotide | Peptide Conjugate Radionuclide Diagnostic radiopharmaceuticals | Neoplasms Urogenital Diseases Other Diseases Nervous System Diseases Digestive System Disorders | PSMA inhibitors | The University of California, San Francisco | Telix Pharmaceuticals (US), Inc. Beijing Novartis Pharma Co. Ltd. Mayo Clinic Novartis Europharm Ltd. Telix Pharmaceuticals Ltd. Advanced Accelerator Applications USA, Inc. Novartis Pharma Schweiz AG Grand Pharmaceutical (China) Co., Ltd. Novartis Pharma KK University of California, Los Angeles Novartis Pharmaceuticals Corp. The University of California, San Francisco Advanced Accelerator Applications (Italy) Srl | Approved | NDA/BLA | United States European Union Japan United Kingdom Canada Australia Germany France Iceland Liechtenstein Norway | 2020-12-01 | - | Priority Review（China） | Gozetotide | - | 68 Ga | - | Gallium GA-68 Gozetotide | - | - | detail > | |
| Lutetium (177 Lu) Vipivotide Tetraxetan | Lutetium (177 Lu) Vipivotide Tetraxetan | Peptide Conjugate Radionuclide Therapeutic radiopharmaceuticals | Neoplasms Urogenital Diseases Digestive System Disorders Nervous System Diseases Other Diseases | PSMA inhibitors | RadioMedix, Inc. | Novartis Pharma AG Novartis Pharmaceuticals Corp. Advanced Accelerator Applications (Italy) Srl Novartis AG China Novartis Institutes for BioMedical Research Co., Ltd. All India Institute of Medical Sciences Endocyte, Inc. Advanced Accelerator Applications SA Novartis Pharma Schweiz AG Novartis Pharmaceuticals Canada, Inc. Advanced Accelerator Applications USA, Inc. Novartis Europharm Ltd. Beijing Novartis Pharma Co. Ltd. Novartis Pharmaceuticals Australia Pty Ltd. Indiana University Novartis Pharma KK | Approved | Approved | United States China European Union Japan Canada Australia Iceland South Korea Liechtenstein Norway | 2022-03-23 | 2025-11-04 | Breakthrough Therapy（United States） Orphan Drug（South Korea） Priority Review（China） | - | DOTA | 177 Lu | - | Lutetium (177 Lu) Vipivotide Tetraxetan | - | - | detail > | |
| [18F]DCFPyL | [18F]DCFPyL | Small molecule drug Diagnostic radiopharmaceuticals | Neoplasms Urogenital Diseases Digestive System Disorders Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases | PSMA inhibitors PET imaging | Progenics Pharmaceuticals, Inc. | Progenics Pharmaceuticals, Inc. Lantheus Medical Imaging, Inc. Curium Pharma UK Ltd. Sidney Kimmel Cancer Center Curium Holding France SASU The Johns Hopkins University | Approved | - | United States United Kingdom Switzerland | 2021-05-26 | - | Priority Review（United States） | - | - | - | - | [18F]DCFPyL | - | - | detail > | |
| Flotufolastat F-18 | Flotufolastat F-18 | Synthetic peptide Diagnostic radiopharmaceuticals | Neoplasms Urogenital Diseases | PSMA modulators PET imaging | Technische Universität München | Blue Earth Diagnostics Ltd. Sinotau Pharmaceutical Group | Approved | Phase 3 | United States | 2023-05-25 | - | - | - | - | - | - | Flotufolastat F-18 | - | - | detail > | |
| FPI-2265 | FPI-2265 | Radionuclide Drug Conjugates (RDC) Therapeutic radiopharmaceuticals | Neoplasms Urogenital Diseases | PSMA modulators | RadioMedix, Inc. | Fusion Pharmaceuticals, Inc. Technische Universität München | Phase 2 | - | - | - | - | - | - | - | 225 Ac | - | FPI-2265 | - | - | detail > | |
| Lutetium-177-PSMA-I&T | Lutetium-177-PSMA-I&T | Peptide Conjugate Radionuclide Therapeutic radiopharmaceuticals | Neoplasms Mouth and Tooth Diseases Urogenital Diseases | PSMA inhibitors | Radboud University Nijmegen | Medical University of Vienna Radboud University Nijmegen | Phase 2 | - | - | - | - | - | PSMA analogue | - | 177 Lu | - | Lutetium-177-PSMA-I&T | - | - | detail > |
Total 430 data
1
2
3
4
5
6
...
42
43
